ACSL3 is found to be upregulated in fibrosarcomas, ER-negative, prostate cancer, melanoma, hepatocellular carcinomas and lung cancer, suggesting that targeting ACSL3 in this context may be clinically relevant for many cancers. The gene discussed is ACSL3; the disease is cancer.